David M. Eddy, MD, PhD; Leonard Schlessinger, PhD; Richard Kahn, PhD
Note: The order of authorship for Drs. Eddy and Schlessinger is alphabetical.
Disclaimer: The views expressed herein are those of the authors and do not necessarily reflect those of Kaiser Permanente or the American Diabetes Association.
Grant Support: This analysis was funded by Kaiser Permanente. The validation of the Archimedes model was funded by a grant from the American Diabetes Association, supported in part by Bristol-Myers Squibb.
Potential Financial Conflicts of Interest: The American Diabetes Association, which provided funding for validation of the Archimedes model, has received grants from Bristol-Myers Squibb, the manufacturer of metformin.
Requests for Single Reprints: David M. Eddy, MD, PhD, 1426 Crystal Lake Road, Aspen, CO 81611; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Eddy: 1426 Crystal Lake Road, Aspen, CO 81611.
Dr. Schlessinger: 633 Swarthmore Avenue, Pacific Palisades, CA 90272.
Dr. Kahn: American Diabetes Association, 1701 North Beauregard Street, Alexandria, VA 22307.
Author Contributions: Conception and design: D.M. Eddy, L. Schlessinger, R. Kahn.
Analysis and interpretation of the data: D.M. Eddy, L. Schlessinger.
Drafting of the article: D.M. Eddy.
Critical revision of the article for important intellectual content: D.M. Eddy, L. Schlessinger, R. Kahn.
Final approval of the article: D.M. Eddy, L. Schlessinger, R. Kahn.
Provision of study materials or patients: D.M. Eddy, L. Schlessinger.
Statistical expertise: D.M. Eddy, L. Schlessinger.
Obtaining of funding: D.M. Eddy, R. Kahn.
Administrative, technical, or logistic support: D.M. Eddy, L. Schlessinger.
Collection and assembly of data: D.M. Eddy, L. Schlessinger.
Eddy DM, Schlessinger L, Kahn R. Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes. Ann Intern Med. 2005;143:251-264. doi: 10.7326/0003-4819-143-4-200508160-00006
Download citation file:
Published: Ann Intern Med. 2005;143(4):251-264.
A previous Markov model–based analysis estimated that use of the Diabetes Prevention Program diet and exercise intervention to forestall diabetes in high-risk people would be cost-effective from a societal perspective.
Using a validated model designed to be more complete and realistic than previous models, the authors estimated that the intervention would cost society about $62 600 per quality-adjusted life-year saved. It would be cost-saving if the annual cost of the intervention decreased from $672 to $100.
This model suggests that the Diabetes Prevention Program intervention costs more per quality-adjusted life-year saved than previously estimated, and health plans and insurers may consider it too expensive to cover.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Endocrine and Metabolism, Diabetes, Coronary Risk Factors, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only